Read by QxMD icon Read

Sirolimus v everolimus

Sho Torii, Qi Cheng, Hiroyoshi Mori, Michael J Lipinski, Eduardo Acampado, Laura E L Perkins, Syed F Hossainy, Stephen D Pacetti, Frank D Kolodgie, Renu Virmani, Aloke V Finn
AIMS: Durable-fluoropolymer coated everolimus-eluting stents (FP-EES) have shown lower rates of stent thrombosis (ST) versus bare-metal stents (BMS) and 1st-generation bioabsorbable-polymer (BP) DES. However, the specific role of the FP in thromboresistance has not been explored. METHODS AND RESULTS: A total of 57 stents were assessed in 3 separate ex-vivo swine arterio-venous shunt-model experiments [1st-shunt-experiment, custom-made fluoropolymer-coated BMS (FP-only) vs...
April 3, 2018: EuroIntervention
Marcos Tascon, Md Nazmul Alam, Germán Augusto Gómez-Ríos, Janusz Pawliszyn
Technologies that efficiently integrate the sampling and sample preparation steps with direct introduction to mass spectrometry (MS), providing simple and sensitive analytical workflows as well as capabilities for automation, can generate a great impact in a vast variety of fields, such as in clinical, environmental, and food-science applications. In this study, a novel approach that facilitates direct coupling of Bio-SPME devices to MS using a microfluidic design is presented. This technology, named microfluidic open interface (MOI), which operates under the concept of flow-isolated desorption volume, consists of an open-to-ambient desorption chamber (V ≤ 7 μL) connected to an ionization source...
February 20, 2018: Analytical Chemistry
C J Li, B Xu, C D Guan, R L Gao
Objective: To compare the long term safety and efficacy of the novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent(Firehawk stent) and permanent polymer coating everolimus eluting stent(Xience V stent) for the treatment of coronary de novo lesions. Methods: This prospective, multi-center, non-inferiority, randomized control trial(TARGETⅠ trial) was performed between August 2010 and April 2011, a total of 460 patients with primary, de novo, single vessel and single coronary lesion from 16 medical centers were enrolled...
November 24, 2017: Zhonghua Xin Xue Guan Bing za Zhi
Hiroyoshi Mori, Dheeraj R Atmakuri, Sho Torii, Ryan Braumann, Samantha Smith, Hiroyuki Jinnouchi, Anuj Gupta, Emanuel Harari, Melsi Shkullaku, Robert Kutys, David Fowler, Maria Romero, Renu Virmani, Aloke V Finn
BACKGROUND: The "very late" clinical outcomes for durable polymer drug-eluting stents and bare metal stents (BMSs) have been shown to be dissimilar in clinical studies. Conceptually, the long-term vascular compatibility of BMSs is still regarded to be superior to drug-eluting stents; however, no pathologic study to date has specifically addressed this issue. We evaluated the very late (≥1 year) pathologic responses to durable polymer drug-eluting stents (cobalt-chromium [CoCr] everolimus-eluting stents [EESs] and stainless steel sirolimus-eluting stents [SS-SESs]) versus BMSs (CoCr-BMSs)...
November 17, 2017: Journal of the American Heart Association
Gheorghe Doros, Joseph M Massaro, David E Kandzari, Ron Waksman, Jacques J Koolen, Donald E Cutlip, Laura Mauri
BACKGROUND: Traditional study design submitted to the Food and Drug Administration to test newer drug-eluting stents (DES) for marketing approval is the prospective randomized controlled trial. However, several DES have extensive clinical data from trials conducted outside the United States that have led to utilization of a novel design using the Bayesian approach. This design was proposed for testing DES with bioresorbable polymer compared with DES most commonly in use today that use durable polymers for drug elution...
November 2017: American Heart Journal
Hiroyoshi Mori, Qi Cheng, Christoph Lutter, Samantha Smith, Liang Guo, Matthew Kutyna, Sho Torii, Emanuel Harari, Eduardo Acampado, Michael Joner, Frank D Kolodgie, Renu Virmani, Aloke V Finn
OBJECTIVES: This study sought to investigate endothelial coverage and barrier protein expression following stent implantation. BACKGROUND: Biodegradable polymer drug-eluting stents (BP-DES) have been purported to have biological advantages in vessel healing versus durable polymer DES (DP-DES), although clinical trial data suggest equipoise. METHODS: Biodegradable polymer-sirolimus-eluting stents (BP-SES), durable polymer-everolimus-eluting stents (DP-EES), and bare-metal stents (BMS) were compared...
December 11, 2017: JACC. Cardiovascular Interventions
David E Kandzari, Laura Mauri, Jacques J Koolen, Joseph M Massaro, Gheorghe Doros, Hector M Garcia-Garcia, Johan Bennett, Ariel Roguin, Elie G Gharib, Donald E Cutlip, Ron Waksman
BACKGROUND: The development of coronary drug-eluting stents has included use of new metal alloys, changes in stent architecture, and use of bioresorbable polymers. Whether these advancements improve clinical safety and efficacy has not been shown in previous randomised trials. We aimed to examine the clinical outcomes of a bioresorbable polymer sirolimus-eluting stent compared with a durable polymer everolimus-eluting stent in a broad patient population undergoing percutaneous coronary intervention...
October 21, 2017: Lancet
Tanjala T Gipson, Michael V Johnston
Tuberous sclerosis complex (TSC) is a multi-system disorder resulting from mutations in either the TSC1 or TSC2 genes leading to hyperactivation of mechanistic target of rapamycin (mTOR) signaling. TSC is commonly associated with autism (61%), intellectual disability (45%), and behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial difficulties that are collectively referred to as TSC-associated neuropsychiatric disorders (TAND). More than 90% of children with TSC have epilepsy, including infantile spasms, and early onset of seizures, especially infantile spasms, is associated with greater impairment in intellectual development compared with individuals with TSC without seizures...
2017: F1000Research
Gennaro Giustino, Rafael Harari, Usman Baber, Samantha Sartori, Gregg W Stone, Martin B Leon, Stephan Windecker, Patrick W Serruys, Adnan Kastrati, Clemens Von Birgelen, Takeshi Kimura, Giulio G Stefanini, George D Dangas, William Wijns, P Gabriel Steg, Marie-Claude Morice, Edoardo Camenzind, Giora Weisz, Pieter C Smits, Sabato Sorrentino, Madhav Sharma, Serdar Farhan, Michela Faggioni, David Kandzari, Soren Galatius, Raban V Jeger, Marco Valgimigli, Dipti Itchhaporia, Laxmi Mehta, Hyo-Soo Kim, Alaide Chieffo, Roxana Mehran
Importance: Women with acute myocardial infarction (MI) undergoing mechanical reperfusion remain at increased risk of adverse cardiac events and mortality compared with their male counterparts. Whether the benefits of new-generation drug-eluting stents (DES) are preserved in women with acute MI remains unclear. Objective: To investigate the long-term safety and efficacy of new-generation DES vs early-generation DES in women with acute MI. Design, Setting, and Participants: Collaborative, international, individual patient-level data of women enrolled in 26 randomized clinical trials of DES were analyzed between July and December 2016...
August 1, 2017: JAMA Cardiology
Mikhail V Blagosklonny
Inhibitors of mTOR, including clinically available rapalogs such as rapamycin (Sirolimus) and Everolimus, are gerosuppressants, which suppress cellular senescence. Rapamycin slows aging and extends life span in a variety of species from worm to mammals. Rapalogs can prevent age-related diseases, including cancer, atherosclerosis, obesity, neurodegeneration and retinopathy and potentially rejuvenate stem cells, immunity and metabolism. Here, I further suggest how rapamycin can be combined with metformin, inhibitors of angiotensin II signaling (Losartan, Lisinopril), statins (simvastatin, atorvastatin), propranolol, aspirin and a PDE5 inhibitor...
May 30, 2017: Oncotarget
A Capron, V Haufroid, P Wallemacq
Immunosuppressive drugs (IS) used in solid organ transplantation are critical dose drugs with high intra- and inter-subject variability. Therefore, IS therapeutic drug monitoring (TDM), mainly as trough levels analysis, is a major support to patient management, mandatory to optimize clinical outcome. Even though transplant patients undoubtedly benefited by this pre-dose (C0) monitoring, the relationship between these C0 concentrations and the incidence of graft rejections remains hardly predictable. Identification and validation of additional biomarkers of efficacy are therefore very much needed...
September 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
Abhishek Sharma, Samin K Sharma, Ajay Vallakati, Akash Garg, Carl J Lavie, Debabrata Mukherjee, Jonathan D Marmur
OBJECTIVE: To evaluate efficacy and safety of long duration dual anti-platelet therapy i.e., >12months (L-DAPT) and short duration DAPT i.e., ≤12months (S-DAPT) after various drug-eluting stent (DES) implantation. METHODS: We searched Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) to identify randomized controlled trials (RCTs) assessing the effect of L-DAPT versus S-DAPT after sirolimus-eluting (Cypher®); paclitaxel-eluting stents (Taxus®); zotarolimus-eluting (Endeavor®) and everolimus-eluting stents (Xience V®) implantation...
July 15, 2016: International Journal of Cardiology
Lisette Okkels Jensen, Per Thayssen, Evald Høj Christiansen, Michael Maeng, Jan Ravkilde, Knud Nørregaard Hansen, Henrik Steen Hansen, Lars Krusell, Anne Kaltoft, Hans Henrik Tilsted, Klara Berencsi, Anders Junker, Jens Flensted Lassen
BACKGROUND: Long-term safety and efficacy for everolimus-eluting stents (EES) versus those of sirolimus-eluting stents (SES) are unknown. OBJECTIVES: This study compared 5-year outcomes for EES with those for SES from the SORT OUT IV (Scandinavian Organization for Randomized Trials with Clinical Outcome) trial. METHODS: Five-year follow-up was completed for 2,771 patients (99.9%). Primary endpoint was a composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), target vessel revascularization (TVR), and definite stent thrombosis...
February 23, 2016: Journal of the American College of Cardiology
N Chebib, C Khouatra, R Lazor, F Archer, C Leroux, D Gamondes, F Thivolet-Bejui, J F Cordier, V Cottin
INTRODUCTION: Pulmonary lymphangioleiomyomatosis (LAM) is a rare disease affecting mainly young women. BACKGROUND: The respiratory manifestations are characterized by a progressive cystic destruction of the lung parenchyma. Extrapulmonary involvement includes benign renal tumours called angiomyolipomas and abdominal lymphatic masses called lymphangioleiomyomas. At the pathological level, the cellular proliferation found in LAM is in part due to the presence of mutations in the tumour suppressor genes TSC1 and TSC2 (Tuberous Sclerosis Complex)...
October 2016: Revue des Maladies Respiratoires
Uwe Christians, Alexander A Vinks, Loralie J Langman, William Clarke, Pierre Wallemacq, Teun van Gelder, Varun Renjen, Pierre Marquet, Eric J Meyer
The immunosuppressants cyclosporine, tacrolimus, sirolimus, everolimus, and probably also mycophenolic acid require therapeutic drug monitoring (TDM)-guided dosing to ensure that blood concentrations are kept within the target range in transplant patients. Reliable, accurate, and precise test methods are therefore essential to effectively monitor levels and to make proper dose adjustments. Data from proficiency testing programs have shown substantial interlaboratory variability. Only few attempts have been made to study the underlying causes...
December 2015: Therapeutic Drug Monitoring
K Orvin, D Carrie, G Richardt, W Desmet, A Assali, G Werner, Y Ikari, K Fujii, J Goicolea, V Dangoisse, A Manari, S Saito, W Wijns, R Kornowski
OBJECTIVE: To demonstrate the safety and efficacy of a new sirolimus eluting stent with bioresorbable polymer, Ultimaster, (BP-SES) compared with everolimus-eluting, permanent polymer, Xience stent (PP-EES) in bifurcation lesions with respect to the freedom from Target Lesion Failure at 1-year. METHODS: Within 1,119 patients enrolled in the CENTURY II randomized controlled multicenter trial, 194 patients were treated for bifurcation lesions and randomized to either BP-SES (n = 95) or PP-EES (n = 99)...
May 2016: Catheterization and Cardiovascular Interventions
Nagendra R Pokala, Rohan V Menon, Siddharth M Patel, George Christopoulos, Georgios E Christakopoulos, Anna P Kotsia, Bavana V Rangan, Michele Roesle, Shuaib Abdullah, Jerrold Grodin, Dharam J Kumbhani, Jeffrey Hastings, Subhash Banerjee, Emmanouil S Brilakis
BACKGROUND: As compared with bare metal stents, first-generation drug-eluting stents (DES) improved post-procedural outcomes in aortocoronary saphenous vein graft (SVG) lesions, but there is limited information on outcomes after use of second-generation DES in SVGs. METHODS: We compared the outcomes of patients who received first- (n = 81) with those who received second-generation (n = 166) DES in SVG lesions at our institution between 2006 and 2013. Major adverse cardiac events (MACE) were defined as the composite of all-cause death, myocardial infarction, and target vessel revascularization...
January 1, 2016: Catheterization and Cardiovascular Interventions
Minoru Ichikawa, Yoshizumi Takei, Toshimitsu Hamasaki, Yoshiyuki Kijima
BACKGROUND: The loss-of-function genotype of cytochrome P450 2C19 (CYP2C19) has been proposed as a risk factor for stent thrombosis in patients with drug-eluting stent implantation. The aim of this study was to clarify the clinical features of patients with angioscopically-detected in-stent mural thrombi (ISMT). METHODS AND RESULTS: Enrolled were 100 stented segments in 55 patients with stable angina (20 bare-metal stents; 39 Cypher sirolimus-eluting stents [SES]; 26 Endeavor zotarolimus-eluting stents [ZES]; 13 Xience V everolimus-eluting stents; and 2 Nobori biolimus-eluting stents)...
2015: Circulation Journal: Official Journal of the Japanese Circulation Society
Pietro Giudice, Tiziana Attisano, Marco Di Maio, Elisabetta M Bellino, Maria V Polito, Cesare Baldi, Francesco Vigorito, Michele R Di Muro, Salvatore D Tomasello, Alfredo R Galassi, Federico Piscione
First generation drug-eluting stent can cause a paradoxical "in-segment" coronary vasoconstriction. This phenomenon was seen with sirolimus, paclitaxel, and, more recently, also with zotarolimus-eluting stent. For the first time, we describe a case of coronary-induced vasoconstriction by everolimus-eluting stents (EES).
December 2014: Interventional Medicine & Applied Science
V Conti, M Grazia, M Romagnoli, G Poletti, S Cristino, G Ciliberti, S Piciucchi, G Mosconi, V Poletti
No abstract text is available yet for this article.
December 2014: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"